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Abstract  1 
Objective: A major characteristic of the autoimmune disease primary Sjögren’s syndrome (pSS) 2 
is salivary gland (SG) hypofunction. Resident salivary gland stem cell (SGSC) inability to 3 
maintain homeostasis and saliva production has never been explained, and limits our 4 
comprehension of mechanisms underpinning pSS.  5 
Methods: SGSCs were isolated from parotid biopsies of controls and patients classified as pSS or 6 
incomplete pSS, according to ACR-EULAR criteria. Self-renewal and differentiation assays 7 
determined SGSC regenerative potential, RNA was extracted for RNASeq analysis, STELA 8 
analysis employed to determine telomere length, and frozen tissue used for immunohistochemical 9 
analysis. 10 
Results: Here we show that SGSCs isolated from pSS parotid gland biopsies are regeneratively 11 
inferior to healthy controls. We demonstrate that SGSCs from pSS biopsies are not only lower in 12 
number and less able to differentiate, but are likely to be senescent, as revealed by telomere length 13 
analysis, RNASeq and immunostaining. We further report that SGSCs exposed to pSS-associated 14 
proinflammatory cytokines are induced to proliferate, express senescence associated genes, and 15 
subsequently differentiate into intercalated duct cells. We also localize p16+ senescent cells to the 16 
intercalated ducts in pSS SG tissue, suggesting a block in SGSC differentiation into acinar cells.  17 
Conclusion: This study represents the first characterization of SGSCs in pSS, and also the first 18 
linkage between an autoimmune disease and a parenchymal premature ageing phenotype. The 19 
knowledge garnered in this study argues that disease modifying anti-rheumatic drugs used to treat 20 
pSS are not likely to restore saliva production, but should be supplemented with fresh SGSCs to 21 
recover saliva production. 22 
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 2 
Between 0.4 and 3.1 million people in the U.S. suffer from the autoimmune disease primary 3 
Sjögren’s syndrome (pSS) 1. Presenting clinically in predominantly women (9:1 ratio), pSS is a 4 
multi-faceted syndrome most often associated with production of autoantibodies (SSA/Ro, 5 
SSB/La), infiltration of the salivary glands with lymphocytes, and hyposalivation (reduced 6 
secretory function of the salivary glands). Other symptoms may include neurological aspects, lung 7 
complaints and chronic fatigue. Lymphocytic infiltration of salivary glands is characterized and 8 
measured clinically by presence of immune foci, gatherings of more than 50 lymphocytes in the 9 
salivary glands, associated with the striated ducts. The periductal infiltrates may evolve into 10 
ectopic lymphoid tissue harboring germinal centers (sites of memory B cell formation). In addition, 11 
the relative number of IgA plasma cells  decreases, in parallel with glandular dominance of IgG 12 
producing plasma cells. Mucosa-associated lymphoid tissue (MALT) lymphomas are also 13 
frequently observed in salivary gland tissue of pSS patients. All these aspects reflect the B-cell 14 
dominated phenotype of pSS 2. Given these characteristic lymphocytic infiltrates, the  logical 15 
conclusion is that lymphocytic infiltration of salivary glands is the causative factor underpinning 16 
hyposalivation. More recent, detailed research however has clearly demonstrated to the contrary 17 
that the correlation between salivary flow and degree of inflammation is poor 3–11. 18 
In healthy SGs, homeostasis is maintained by proliferation and differentiation of tissue resident 19 
salivary gland stem cells (SGSCs). According to one of the prevailing views in the field these cells 20 
reside in striated ducts, from where they differentiate first towards intercalated ducts and 21 
subsequently to acinar cells 12–16. Other groups have identified progenitor cell populations within 22 
the acinar cell subset, and alternatively also suggested that acinar cells themselves are capable of 23 
5 
 
maintaining SG homeostasis through self-replication 17,18. Regardless of whichever niche you 1 
consider SGSCs to reside in, the apparent lack of ability of SGSCs to maintain SG homeostasis in 2 
pSS has never been explained, and likely contributes to hyposalivation development in pSS.  Here 3 
we employ our recently developed protocols for SGSC isolation to probe involvement of SGSCs 4 
in pSS 12–14,16,19. We demonstrate that SGSCs  in pSS are likely to be senescent, a phenotype 5 
that may be induced by exposure to pSS-associated pro-inflammatory cytokines. 6 
Materials and Methods 7 
Source of salivary gland tissue 8 
For healthy control biopsies, parotid SG tissue was obtained from donors (after informed consent 9 
and IRB approval (METC2016/010) who were treated for a squamous cell carcinoma of the oral 10 
cavity. In these patients an elective head and neck dissection procedure was performed. During 11 
this procedure parotid SG is exposed and removed as part of the dissection procedure.  This tissue 12 
does not contain malignant cells, as oral squamous cell carcinoma does not disseminate to the 13 
parotid salivary gland. For biopsies from pSS and incomplete pSS patients, biopsies were taken 14 
during routine biopsy for pSS diagnosis work-up trajectory. Patients were classified as pSS if 15 
fulfilling the 2016 ACR-EULAR criteria for pSS 20. Incomplete pSS patients did not fulfill these 16 
criteria, were not taking hyposalivation-inducing medication, but did demonstrate either objective  17 
symptoms of dry mouth or SSA autoantibody presence. All patients gave IRB consent and 18 
approval (METc 2016/010). 19 
Stem cell isolation 20 
Parotid SG biopsies were harvested from oral squamous cell cancer patients with healthy parotid 21 
gland tissue , incomplete pSS patients and pSS patients were collected after surgery into Hank’s 22 
Balanced Salt Solution (HBSS) containing 1 % bovine serum albumin (BSA; Invitrogen). Biopsies 23 
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were mechanically digested using the gentleMACS dissociator (Miltenyi Biotec) or manually with 1 
scissors, and simultaneously subjected to digestion in HBSS/1% BSA buffer containing 0.63 2 
mg/mL collagenase II (Invitrogen) and 0.5 mg/mL hyaluronidase (Sigma Aldrich), and calcium 3 
chloride at a final concentration of 6.25 mM, for 30 minutes at 37 ˚C. Forty mg of tissue was 4 
processed per 1 mL buffer volume, total volume was adjusted according to biopsy weight. 5 
Digested cells were collected by centrifugation, washed twice in HBSS/1 % BSA solution, and 6 
passed through 100 µm cell strainers (BD Biosciences). Resultant cell suspensions were collected 7 
again by centrifugation and resuspended in SGSC medium  consisting of 40 % Dulbecco’s 8 
modified Eagle’s medium:F12 medium, Pen/Strep antibiotics (Invitrogen), Glutamax (Invitrogen),  9 
50 % Wnt3a conditioned medium, 10 % R-spondin conditioned medium (derived from the RSPO-10 
1 cell line, Amsbio), 20 ng/mL epidermal growth factor (EGF) (Sigma Aldrich) 20 ng/mL 11 
fibroblast growth factor-2  (FGF2) (Sigma Aldrich), N2 (Invitrogen), 10 mg/mL insulin (Sigma 12 
Aldrich), and 1 mM dexamethasone (Sigma Aldrich ), 10 µM Rho Kinase Inhibitor (Abcam), 5 13 
µM TGFß inhibitor  (A8301, ToCris Bioscience) and 12.5 ng/mL Noggin (Peprotech).  800,000 14 
of primary isolate cells were resuspended in 25 µL of SGSC medium, combined with 50 µL of 15 
Basement Membrane Matrigel  (BD Biosciences) and deposited in center of  12-well tissue culture 16 
plates. After letting the gels solidify (20 minutes at 37 ˚C), 1 mL of stem cell medium was added 17 
per well. After 3-5 days of culture, primary spheres formed were released from Matrigel by 18 
incubation in 1 mg/mL Dispase (1 hour at 37 ˚C; Sigma). Primary spheres of a minimum size of 19 
50 µM were counted and used to establish primary sphere yield per mg of biopsy material. To 20 
correct primary sphere yield for the site of biopsy, HC and pSS primary sphere yields were 21 
multiplied by factors of 4.1 and 11.95 respectively. Multiplication factors were derived from yield 22 
of primary spheres isolated from the SGSC-rich area, according to van Luijk et al 21. 23 
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Cytospot preparation and quantification 1 
100 uL of cell suspension obtained after SGSC isolation protocol was added into cytospin funnel, 2 
after pre wetting of coated microscope slides with 1 % BSA/PBS solution. After centrifugation at 3 
300 rpm for 2 minutes, slides were air dried, and fixed with 4 % PFA at room temperature for 20 4 
minutes. Haematoxylin and eosin staining was then performed as per standard protocols. Number 5 
of acinar and ductal cells was determined by capturing images of 3 areas of the cytospot per 6 
sample. Total cell number  in each areas was determined by counting hematoxylin stained nuclei. 7 
Acinar cells were identified by characteristic triangular morphology and predominant hematoxylin 8 
staining. Ductal cells were identified  by heavily eosin stained cytoplasm. Proportion of each cell 9 
type was expressed as percentage of total cells. For CD45+ quantification, cytospots were fixed as 10 
above, then permeabilized in 100 % ethanol (20 minutes at -20 ˚C), washed in PBS and then 11 
incubated in mouse anti CD45 antibody (DAKO: 1 hour at RT) diluted 1:100 in 1 % BSA 12 
0.05/Tween/PBS. Following PBS washing, goat anti-mouse secondary antibody conjugated to 13 
Alexaflour-488 was added onto cytospots at 1:300 dilution in 1 % BSA / 0.05 Tween / PBS, and 14 
incubated at room temperature for 1 hour. Following final PBS washes, nuclei were counterstained 15 
with DAPI and cytospots visualized using the a Leica 6000 Series microscope.   16 
Flow cytometry and FACS of salivary gland isolate 17 
Cell suspension post-isolation where appropriate were dispersed to single cells. Cells were 18 
immunolabeled with antibodies against the following human proteins, conjugated to fluorophores 19 
as indicated:  EpCAM-eFlour660 (eBioscience, 1:20), CD45-PE-Cy5  (Biolegend, 1:50), CD19-20 
BUV737 (eBioscience, 1:50), CD3-APC-eF700 (eBioscience, 1:50), CD56-PE-Cy7 (Biolegend, 21 
1:50), CD4-APC-eF780 (eBioscience, 1:50), CD24-PE-Cy7 (Biolegend, 1:20), Ki67-FITC 22 
(Thermofisher Scientific, 1:200). For intranuclear staining for Ki67, the eBioscience Foxp3 23 
8 
 
Transcription Factor Buffer Set was used, as per manufacturer’s instructions. Staining for K14 and 1 
SMA was performed in two steps using rabbit anti human K14 (Abcam, 1:100) and mouse anti 2 
human SMA (DAKO, 1:100) and Alexaflour-647-conugated secondary antibody (1:300). 3 
Antibodies were added in total volume of 100 µL 0.5 % BSA/PBS  with 2mM EDTA (staining 4 
buffer), containing a maximum of 1 million cells. Staining was performed for 20 minutes on ice. 5 
Cells were collected by centrifugation and resuspended staining buffer for analysis with the LSR-6 
II flow cytometer (BD Biosciences). Live-dead discrimination was performed using  80 ng / mL 7 
propidium iodide (Thermofisher). For FACS sorting of EpCAM+ cells from salivary gland isolate, 8 
staining was performed as above, with addition of 0.1 M Magnesium Sulphate (Sigma) and 50 µg 9 
/ mL DNase (Sigma)  into cell suspension to prevent cell clumping. Collected CD45+ were 10 
harvested into stem cell medium collected by centrifugation and plated into Matrigel as described 11 
above. Gating strategy for flow cytometric analysis and FACS is shown in Supplementary Fig. 5. 12 
Self-renewal 13 
Following release of primary spheres from Matrigel as above, cells were dispersed to form single 14 
cell suspensions using 0.05 % trypsin-EDTA (Invitrogen), enumerated, and concentration adjusted 15 
to 0.4 x 106 cells per mL in SGSC medium. 25 µL of this cell solution was combined with 50 µL 16 
volumes of Basement Membrane Matrigel and deposited in the center of 12-well tissue culture 17 
plates. After solidifying the Matrigel for 20 minutes at 37 ˚C, gels were covered in stem cell 18 
medium as defined above. Organoids appeared 2–3 days post-seeding of single cells in Matrigel. 19 
Ten days after seeding, Matrigel was dissolved by incubation with Dispase enzyme as above. 20 
Organoids over 50 µM in diameter were enumerated,  cells  were processed to a single cell 21 
suspension using 0.05 % trypsin-EDTA and cell number determined. These data were used to 22 
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generate the organoid formation efficiency and population doublings. Population doublings (pds) 1 
were calculated according to the following formula: 2 
 3 
 Encapsulation in Matrigel was repeated to generate the next passage. This cycle was repeated  four  4 
times (4 passages). At each  the end of each passage an image was captured of the cells, using the 5 
Olympus CKX53 microscope and DP2-SAL software.  6 
Mature organoid formation assay 7 
For mature organoid formation assays, organoid cultures were supplemented with  1µM 8 
Isoproterenol was added per gel. Mature organoid formation was monitored over a two week 9 
period.  10 
RNASeq 11 
Total RNA was extracted from stem cells by using Absolutely RNA Miniprep kit (Agilent 12 
Technologies, CA. Cat: 400800) followed the manufacturer’s recommendations. The integrity of 13 
RNA were examined by Agilent 2100 bioanalyzer. Subsequent sequencing was performed by 14 
using SMART-Seq v4 Ultra Low Input RNA Kit (Clontech, Cat: 634890) and Nextera XT DNA 15 
Library Prep Kit (Illumine, Cat: FC-131-1096) followed manufacturer’s recommendations, 16 
prepared DNA libraries were sequenced on HiSeq 2500 System. Data quality assessment was 17 
performed to understand main source of variability, differential expression analysis and 18 
visualization were performed in R (packages PVCA, EdgeR and PHeatmap). Metacore pathway 19 
database was used for pathway enrichment analysis 20 
Cytokine incubations with SGSCs 21 
Cytokines were purchased as follows: human IL-6 (Peprotech; 200-06A) human IFNα (R&D 22 
Systems; 11100-1),  and human TNFα (Peprotech; 300-01A) and reconstituted according to 23 
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manufacturer’s directions. Dilutions for co-culture with cytokines were performed in such a 1 
manner that volume of cytokine added to medium was always 1 % of total medium volume. 2 
Medium was refreshed 2 times within the passage (days 3 and 6), in parallel with control cultures. 3 
Whole mount and tissue immunocytochemistry 4 
Mature organoids were released from Matrigel using Dispase, collected in round-bottomed 96-5 
well plates, and fixed in 2 % PFA for 10 minutes. Frozen tissue sections were cut at a thickness of 6 
8 µM, and fixed in 2 % PFA for 5 minutes. Staining  was performed for all samples from this point 7 
following instructions of the Tyramide Signal amplification kit (Thermofisher). After hydrogen 8 
peroxide blocking and general blocking, primary antibodies were incubated with organoids, 9 
mature organoids or tissue sections overnight in PBS at 4 degrees. Dilutions of primary antibodies 10 
used for immunostaining were: rabbit anti-human amylase (1:100, Sigma A2863); rabbit anti-11 
human aquaporin-5 (AQP-5), rabbit anti-human EpCAM (antibody as FACS analysis), mouse anti 12 
human IL6R (1:100; Thermofisher clone B-R6), mouse anti human TNFR1 (Thermofisher clone 13 
H398), rabbit anti human IFNαR (1:100; Abcam 62693), mouse anti-human p16 (1:100; Abcam 14 
54210) and mouse anti human smooth muscle actin (1:100, Dako M0851). Nuclear counterstaining 15 
was performed with Hoechst 33342, at 1:300 dilution from 10 mg / mL stock solution, for 10 16 
minutes at room temperature. Immunostainings were visualized using the Leica TCS SP8 confocal 17 
laser scanning microscope and Leica Application Suite software.  18 
Telomere analysis 19 
DNA was extracted from human salivary gland stem cells using a QIAmp DNA Micro Kit 20 
(Qiagen). Single telomere length analysis (STELA) was carried out at the XpYp telomere as 21 
described previously (Capper et al. 2007). Briefly 1 µM of the Telorette2 linker was added to 10 22 
ng of purified genomic DNA in a final volume of 40 µL per sample. Multiple PCRs were 23 
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performed for each test DNA in 10 µL volumes incorporating 250 pg of DNA, 0.5 µM of the 1 
telomere-adjacent and Teltail primers, 75 mM Tris-HCl pH8.8, 20 mM (NH4)2SO4, 0.01% Tween-2 
20, 1.5 mM MgCl2, and 0.5 U of a 10:1 mixture of Taq (ABGene) and Pwo polymerase (Roche 3 
Molecular Biochemicals). The reactions were processed in a Tetrad2 Thermal Cycler (BioRad). 4 
DNA fragments were resolved by 0.5 % TAE agarose gel electrophoresis and identified by 5 
Southern hybridization with a random-primed a-33P-labeled (PerkinElmer) TTAGGG repeat 6 
probe, together with probes specific for the 1 kb (Stratagene) and 2.5 kb (BioRad) molecular 7 
weight markers. Hybridized fragments were detected using a Typhoon FLA 9500 Phosphorimager 8 
(GE Healthcare). The molecular weights of the DNA fragments were calculated using a Phoretix 9 
1D Quantifier (Nonlinear Dynamics). 10 
qPCR 11 
Total RNA as was extracted from cultured cells as appropriate using the RNeasy Microkit 12 
(Qiagen), including DNase incubation, as per manufacturer’s instructions. One µg of total RNA 13 
was reverse transcribed to cDNA using 0.5 µg oligo(dT)15-18 primers, 1.0 mM dNTPs, 1X Reaction 14 
Buffer,  20U Ribolock  and 200 U of RevertAid Reverse Transcriptase (all Thermo Fischer 15 
Scientific), in a total volume of 20 µL  per reaction.  cDNA product was diluted ten-fold in water 16 
and used at this concentration for qPCR. qPCR was performed using SsoAdvanced Universal 17 
SYBR Green qPCR Mastermix (Biorad), with primers at a final concentration of  500 nM from a 18 
10 µM stock. 2.5 µL of diluted cDNA was used per reaction, and all reactions were performed in 19 
triplicate, in a total volume of 10 µL.   Primer sequences can be found in Table S1. A 2-step qPCR 20 
cycle with the BioRad iCycler qPCR machine was used for target amplification according to 21 
SSoAdvanced Universal SYBR Green  Mastermix instructions,  and CFX Manager software for 22 
analysis.  23 
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 1 
Results  2 
Salivary gland stem cells from pSS patients show reduced regenerative potential  3 
We began by isolating SGSCs from parotid SG biopsies of control patients with healthy SGs (HCs) 4 
and pSS patients fulfilling the ACR-EULAR classification criteria 20. SGSCs are initially cultured 5 
from processed biopsies as primary spheres, in Wnt-containing medium. Three to five days later, 6 
spheres are dispersed to single SGSCs, and expanded in a ‘self-renewal assay’. The cell suspension 7 
generated by the isolation process from pSS biopsies contained significantly less epithelial cells 8 
than HC biopsies and significantly more CD45+ leukocytes, based on cell morphology and 9 
immunostaining on cytospots (Supplementary Figure 1, Supplementary Figure 2A-C). As 10 
previously reported for minor SGs, we detected a high proportion of B-cells and a predominance 11 
of CD4+ T-cells within the flow-cytometry-defined CD45+ fraction of the biopsy isolate 12 
(Supplementary Figure 2D,E) 22. SGSCs are epithelial cell adhesion molecule (EpCAM)hi in 13 
nature. The number of both spheres generated per EpCAMhi cell  and yield of spheres per mg of 14 
biopsy was significantly lower (10 fold difference) from biopsies from pSS patients compared to 15 
HCs (Figure 1A,B, Supplementary Figure 2F). Data are presented normalized to mg of tissue to 16 
take account of the larger healthy salivary gland biopsies obtained.  Primary sphere yield was not 17 
correlated with focus score (lymphocytic infiltration), supporting studies suggesting infiltration 18 
does not determine SG function (Supplementary Figure 2G).  19 
We have previously demonstrated that SGSC yield decreases with age and that more SGSCs are 20 
present closest to the facial nerve in the parotid gland 21,23. Neither donor age  or biopsy site  was 21 
responsible for the decreased yield of SGSCs from pSS biopsies (Supplementary Figure 2H,I). 22 
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Stem cells are classically defined by their ability to proliferate and differentiate. When SGSCs 1 
from pSS biopsies were cultured as organoids to assess their proliferation capacity, we observed a 2 
significantly (up to 5-fold) lower self-renewal capability compared to HCs (Figure 1C-E)13. FACS 3 
selection of EpCAMhi cells from pSS biopsies, thus after removal of infiltrating leukocytes, did 4 
not rescue self-renewal potential of pSS-SGSCs, indicating that sole presence of CD45+ cells in 5 
SGs of pSS patients is not responsible for the regenerative deficits observed (Supplementary 6 
Figure 3). Healthy SGSCs can be induced to proliferate and differentiate from organoids into α-7 
amylase expressing mature organoids (Figure 1F,G). The lack of proliferative capabilities of 8 
SGSCs from pSS biopsies is reflected also in their greatly diminished ability to form mature 9 
organoids (Figure 1H). These data imply that the relatively few SGSCs present in pSS SGs harbor 10 
also defects in differentiation ability. 11 
Salivary gland stem cells in pSS undergo extensive proliferation 12 
In order to elucidate early events in SG pathology development in pSS which are not influenced 13 
by mass lymphocytic infiltration, we focused on patients classified as ‘incomplete pSS’ patients. 14 
These patients have some hallmarks of pSS (outlined in Supplementary Table 2) but with no 15 
positive lymphocyte focus score. This patient cohort was further not taking medication known to 16 
cause dry mouth complaints, all registered complaints of dry eyes and mouth associated with pSS 17 
development and did not fulfil the ACR-EULAR criteria. We consider these features indicative of  18 
early SG pathology development in pSS. When SGSCs were isolated from these patients, we 19 
observed that primary sphere yield from a small proportion (2/10) of these biopsies was markedly 20 
greater than the median of the HCs (Figure 2A). The yield of primary spheres from the remaining 21 
biopsies was comparable with pSS biopsy yield already demonstrated. Reasoning that the 2/10 22 
patients with high yield represent an earlier disease stage24, we theorized that SGSCs receive 23 
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mitotic stimuli early in pSS. We performed RNASeq on organoids cultured  from patients with 1 
incomplete pSS to investigate early events in pSS, and observed a cohort of 101 significantly 2 
upregulated genes in SGSCs from biopsy negative patients compared to HCs (p<0.01, Log10 fold 3 
change ≥2, Figure 2B).  4 
When examined further, 18 of these genes were involved in cell cycle progression (both its 5 
promotion and inhibition) and DNA replication (Figure 2C, Figure S4). As shown in Figure 2C 6 
and Figure 2D, the β-galactosidase-like gene GLB1L2 was also significantly upregulated. B-7 
galactosidase expression is associated with cellular senescence and ageing. Hypothesizing that 8 
SGSCs in pSS disease progression become senescent, we examined the telomere lengths of 9 
organoids cultured from pSS patients with positive SG biopsy evaluations (i.e. with lymphocytic 10 
infiltration), representing a later phase of pSS in terms of SG pathology. STELA analysis of 11 
telomere length revealed short telomeres of less than 4.5kb in length, in SGSCs from biopsy 12 
positive pSS patients (Figure 2E,F, clinical characteristics in Supplementary Table 2). Mean length 13 
of the lowest 10% of telomeres in HC SGSCs was significantly greater (4.80kb) compared to pSS 14 
SGSCs (1.59kb), suggesting  that pSS SGSCs have a more extensive replicative history (Figure 15 
2G). Mean ages of HC and pSS SGSC donors from which telomere analysis was performed were 16 
77.3 and 61.5 years respectively, confirming that telomere difference was not due to advanced age 17 
of pSS SGSC donors. 18 
Proinflammatory cytokines include proliferation and differentiation of healthy salivary gland 19 
stem cells 20 
pSS is an autoimmune disease associated with glandular presence of classic proinflammatory 21 
cytokines, as exemplified by IFNα, TNFα and IL-622. Pro-inflammatory cytokines within the 22 
glandular tissue could provide mitotic signals driving SGSC exhaustion in pSS, leading to a 23 
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senescent ageing-like phenotype and ultimately hyposalivation. Considering the low yield of 1 
SGSCs from pSS patients, and in order to model the earliest phases of pSS, we employed HC 2 
SGSC cultures to investigate this hypothesis. qPCR and immunostaining of HC SGSC organoids 3 
at passage 2 demonstrated that HC SGSCs express receptors for the proinflammatory cytokines 4 
IFNα, TNFα and IL6 (Supplementary Figure 5, primers in Supplementary Table 1). When HC 5 
SGSCs were incubated from passages 1-4 with a cocktail of pro-inflammatory cytokines at 6 
concentrations matching those found in pSS patients’ serum (IFNα 500 pg/mL; TNFα 40 pg/mL; 7 
IL-6 30 pg/mL) 25, we observed initially a significant increase in organoid formation efficiency, 8 
followed by a decrease to significantly below the levels of control cells (Figure 3A,B). Incubation 9 
with single cytokines did not induce significant proliferative effects, even at higher doses 10 
(Supplementary Figure 6). At passage 1 following cytokine exposure, expression of genes 11 
promoting cell cycle progression (CDK4, CDK6, CDC20), inhibiting cell cycle (E2F1, CDKN2D) 12 
and promoting senescence (p16 and p21) were upregulated (Figure 3C). Through definition of 13 
SGSC subsets using cell surface markers and costaining with the proliferation marker Ki67 14 
(Supplementary Figure 7a-b), we also show that SGSCs resident in the basal layer of striated ducts 15 
(BSD cells) are responsible for the proliferation observed (Supplementary Figure 7c). We also 16 
suggest that proinflammatory cytokines induce differentiation of basal striated duct cells into 17 
intercalated ducts (ID cells) (Supplementary Figure 7c,d). Finally, p16 immunostaining was 18 
performed on sections of SG tissue in order to determine where senescent cells were located in 19 
situ. p16+cells were found mostly in intercalated ducts in incomplete and complete pSS tissue. In 20 
contrast, p16+ cells in HC SGs were found dispersed through the tissue, illustrating their full 21 
differentiation potential (Figure 3D-G). 22 
Discussion  23 
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The origins of hyposalivation development in pSS have never been fully elucidated, although 1 
many studies have now firmly established that its development cannot be fully explained by extent 2 
of lymphocytic infiltration 3–9. Using salivary gland stem cells as tool to probe SG dysfunction in 3 
pSS, we show here that parotid gland biopsies of pSS patients contain fewer SGSCs, with reduced 4 
proliferation, differentiation potential and shortened telomeres. Shortened telomeres imply that the 5 
SGSC pool has an extensive replicative history, the reason for which we propose are two-fold. 6 
Firstly, the parenchymal epithelium, e.g. in pSS, non-stem ductal cells and saliva producing acinar 7 
cells have been demonstrated to undergo enhanced levels of apoptosis, from sources intrinsic and 8 
extrinsic to the cells themselves. Extrinsically, the action of cytokines, cytotoxic T cells and NK 9 
cells all promote apoptosis 26. Additionally, a disorganized extracellular matrix in pSS salivary 10 
glands may account for acinar cell loss by anoikis 27. Intrinsically, epithelial cells have been 11 
recently demonstrated to express defective levels of the anti-inflammatory mediator PPARɣ, 12 
resulting in increased activity of the NFκB and IL-6 pathways, but also rendering them more 13 
susceptible to cell death 28–33. Similarly, levels of the ubiquitin-editing protein A20, a negative 14 
regulator of NFkB was down-regulated in salivary gland epithelial cells from pSS patients 15 
compared to healthy subjects 34.  Depletion thus of the parenchymal cell pool via intrinsic and 16 
extrinsic mechanisms together likely stimulate SGSC proliferation and differentiation into acinar 17 
cells, in an attempt to maintain the saliva producing capacity of the SGs. 18 
Secondly, as we have demonstrated here, proinflammatory cytokines exert a direct effect on 19 
proliferation of SGSCs. In other model systems, and most extensively in the well characterized 20 
intestinal stem cell niche, proinflammatory cytokines have also been reported to exert a 21 
proliferative effect, mediated by modulation of the stem cell associated Wnt, Notch and YAP-TAZ 22 
pathways, suggesting that cross-talk between stem cells and the elements of the immune system 23 
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may underlie many disease manifestations 35–39. Cytokine production in the case of pSS may be 1 
derived from neighboring epithelial cells signaling in a paracrine fashion. The production and 2 
secretion of pro-inflammatory cytokines by epithelial cells has been demonstrated in long term 3 
epithelial culture systems and in situ  31,40–43. Following release of  damage- and pathogen-4 
associated molecular patterns (DAMPS/RAMPs), for example molecules such as HMGB1 and 5 
viral antigens, pattern recognition receptor (PRRs) on epithelial cells may be activated, 6 
culminating in epithelial cell autonomous NFkB pathway activity, cytokine production and 7 
paracrine signaling to neighboring SGSCs 32,33. Indeed, the dysregulated NFkB pathway seen in 8 
pSS may account for the sustained pro-inflammatory cytokine production by glandular epithelial 9 
cells 32,34.     10 
In a healthy scenario, one prevailing stem cell theory dictates that salivary gland stem cells reside 11 
in the striated ducts, proliferate and differentiate into intercalated ducts, and then finally into saliva-12 
producing acinar cells. We have shown presence of senescent cells in intercalated ducts of pSS 13 
salivary glands. This suggests a blockade in ability of SGSCs to further differentiate into acinar 14 
cells, presumably due to having reached their regenerative limit, similar to poor mature organoid 15 
differentiation potential we demonstrate in vitro. Clinically, our data suggest that screening patient 16 
SGs or saliva for senescence biomarker expression may indicate the extent of SGSC exhaustion. 17 
We predict further that clinical interventions aimed at preventing hyposalivation development need 18 
to occur before appearance of high levels of senescent markers in SGs or saliva. The present study 19 
also suggests, critically, that effective interventions to cure established hyposalivation by targeting 20 
the inflammatory process are not likely to involve only immune signal blockade; rather the 21 
replenishment of SGSCs stocks in conjunction with resolving the inflammation. Plausible 22 
strategies include SGSC manufacture using induced pluripotent stem cell technologies. 23 
18 
 
In summary, we show for the first time an ageing phenotype as a potential causative agent for the 1 
lack of SG repair in the auto immune disease pSS, and link this to possible future clinical strategies. 2 
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Figure legends: 3 
Fig. 1. Salivary gland stem cells from pSS patients show reduced regenerative potential. A) 4 
Microscopy of primary spheres isolated from HC and pSS biopsies. White arrows denote 5 
organoids. B) Primary sphere yield quantification per EpCAMhi cell in SGSC isolate from 6 
pSS biopsies and HCs. n = 6 for HCs, 9 for pSS biopsies. *= p < 0.05, student’s t- test. C) 7 
Microscopy of organoid cultures from HC and pSS SGSCs. D) Organoid forming 8 
efficiency of HC and pSS self-renewal cultures. n=27 for HC at all passages. n=12, 16, 9 9 
and 6 for pSS at passages 1-4 respectively. Bar height represents mean, error bars are 10 
S.E.M. *=p<0.05,**=p<0.01. Two-way ANOVA and Bonferroni post-hoc testing. E) 11 
Cumulative population doublings of HC and pSS SGSCs. n = 26 for HC passages 1-3 and 12 
24 for passage 4. n=10,5,4 and 2 for pSS at passages 1-4 respectively. Bar height represents 13 
mean, error bars are S.E.M. **=p<0.01. Two way ANOVA and Bonferroni post-hoc 14 
testing. F) Mature organoids formed from a HC SGSC in phase contrast microscopy. G) 15 
Immunocytochemical staining of  acinar cell associated amylase, in a HC derived mature 16 
organoid. Inset shows control without anti-amylase antibody to demonstrate staining 17 
specificity. H) Attempted mature organoid formation from pSS SGSCs.  18 
Fig. 2. Salivary gland stem cells from pSS patients are more likely to be senescent. A)  Primary 19 
sphere yield from HC, incomplete pSS and pSS patients. n=73, 10 and 18 for HC, 20 
incomplete pSS and pSS groups respectively. pSS group from Fig. 1b is used for 21 
comparison. Line represents median. Yellow points represent SGSCs with unusually high 22 
yield. B) Volcano plot resulting from RNASeq analysis comparing HC and incomplete pSS 23 
25 
 
SGSC transcriptomes. Orange box denotes genes whose expression is ≥ Log10 2-fold 1 
higher in pSS SGSCs, with a p<0.01. C) Upregulated cell cycle progression promotion 2 
(green), and inhibition (red) genes identified from RNASeq, including the β-galactosidase-3 
like gene (GLB1L2; blue). Dashed line represents mean HC expression. n=6 HCs, 3 pSS. 4 
D) Raw expression values for GLB1L2. E) STELA analysis of SGSC telomere lengths 5 
from biopsy-positive pSS patients and HC biopsies show outlying small (<4.5 kb) 6 
telomeres in pSS SGSCs samples. F) Quantification of telomere lengths in healthy control 7 
and  pSS SGSCs. Red text denotes percentage of telomeres with a length <4.5kb. G) Length 8 
analysis of lowest 10% of telomeres in HC and biopsy positive pSS patient SGSCs. n=3 9 
patients per group. Bar height represents mean, error bars are S.E.M. Student’s t-test. *= 10 
p≤0.05.  11 
Fig. 3. Parotid SGSC organoid cultures proliferate upon exposure to a proinflammatory cocktail 12 
and express cell cycle and senescence genes. p16+ senescent cells localize to the 13 
intercalated ducts of incomplete pSS and  pSS SG tissue. A) Phase contrast microscopy of 14 
healthy SGSCs at passages 1-4, incubated with (+cytokines) and without (control) the 15 
proinflammatory cytokine cocktail. B) Quantification of organoid formation efficiency of 16 
SGSCs exposed to proinflammatory cytokines, compared to control cells. n ≥7 separate 17 
patient isolations at each passage. Error bars represent SEM. * p<0.05, *** p<0.001, Two 18 
Way ANOVA. C) Expression of cell cycle associated genes in SGSCs exposed to 19 
proinflammatory cytokines. Cells were harvested at the end of passage 1 for qPCR analysis. 20 
n=2 separate patient isolations. Error bars represent SEM. D-G) Immunohistochemical 21 
staining for p16 senescence marker in incomplete pSS (D,E), pSS (F) and healthy control 22 
(HC, F) tissue, counterstained with epithelial growth factor receptor (EGFR) to mark all 23 
26 
 
ductal cells. G is high resolution images of red boxed area in E. ID = intercalated duct. 1 
Ages of tissue donors were 50, 73 and 31 years respectively for HC, incomplete pSS and 2 
pSS, indicating that increased p16+ intercalated duct cells was not due to advanced age of 3 
donor. 4 
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